Clinical Trial Update: Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating durvalumab and tremelimumab with or without hepatic arterial infusion chemotherapy in hepatocellular carcinoma. The study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: UNICANCER | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: RECRUITING